The purpose of the study was to examine the psychometric properties of the revised Liverpool Seizure Severity Scale. The scale has been adapted to increase its content validity and its potential for detecting change attributable to antiepileptic drug treatment. Ninety-seven patients completed the revised scale of which 32 completed it for both major and minor seizures. Reliability of the revised scale was conducted using assessment of internal consistency and test-retest. T-tests were conducted to assess the ability of patients to differentiate between major and minor seizures on scores of the seizure-severity scale. The psychometric properties of the scale were not adversely affected by either the increase in the number of items or the additional response scores. Patients completing the two scales of major and minor seizures were able to reliably differentiate between the two. We have attempted to improve the Liverpool Seizure Severity Scale in order to enhance its reliability, validity and sensitivity to change. The amendments we have made have not adversely affected its psychometric properties and we hope that it will make it more acceptable for use in clinical trials of new antiepileptic drug treatment. The revised scale is currently being applied to a number of clinical trials.
INTRODUCTION
In the assessment of the efficacy of treatment for epilepsy, seizure frequency is the commonest and often the only end point usedl*2. A good outcome for an antiepileptic drug trial is reported if an individual patient achieves a greater than 50% reduction in seizure frequency without any serious adverse drug effects, and the reported efficacy of new antiepileptic drugs is based on the number of patients who achieve this level. However, patients would agree that such a reduction, whilst worthwhile, is not necessarily satisfactory3. In the assessment of the outcome of surgery for patients with intractable epilepsy, a reduction in seizure frequency is also regarded as the principal measure of efficacy4 and is usually determined by the proportion of patients becoming seizure free, although other variables, including social adjustment and psychological status, have sometimes been taken into accoun+.
There are several reasons why seizure frequency alone is an inadequate means of assessing the efficacy of treatment for epilepsy, and these have been well documented6. In clinical trials antiepileptic drugs 1059-1311/98/030201 + 05 $12.00/O may have the potential to modify the severity of a seizure, as perceived by the patient, without necessarily reducing the frequency. This is important, since previous research has demonstrated that patients' perceptions of the severity of their seizures may be more important than seizure frequency in determining the psychosocial well being of patients with poorly controlled epilepsy', '. While it is generally accepted that manifestations of seizures vary between individuals they tend to be stereotyped within individuals and so patients can classify their severity according to their own expetience and the descriptions of their seizures given by regular eye witnesses. People with frequent seizures are also often able to differentiate between major and minor seizures based on a number of factors including whether or not they fall to the ground, the duration of loss of consciousness, and time taken to recover from the seizure and return to their normal activity. The advantages of a patient-based scale over a physicianbased scale have been well documented9. A measure based on patients' perception of seizure severity is more likely to reflect what a patient experiences during a seizure and may be more sensitive to subjective changes in the seizure experience which may be attributable to treatment. Earlier attempts to quantify seizure severity were based on physicians reports" and more recently have been developed to ask physicians to judge seizure severity on the basis of patients' reports' ' . The Liverpool Seizure Severity Scale was designed to quantify patients' own perceptions of changes in seizure severity during the course of a clinical trial of lamictal, a new antiepileptic drug. The development of the scale rested on the assumption that seizure severity is comprised on two factors: patients' perceptions of control over their seizures and the perceived severity of the ictal and postictal phenomena. In the original version the scale consisted of 16 items: percept of control subscale (percept), six items; perceived ictal/postictal severity (ictal/postictal), ten items. Each item was scored on a l-4-point Likert response scale. The reliability and validity of the scale was established prior to its use in a clinical tria16, and the responsiveness of the ictal/postictal scale was demonstrated in a doubleblind crossover study of lamictal".
A number of limitations of the scale were identified from our previous work and these included problems with the comprehensiveness of the scale, its responsiveness and the ability of the scale to cope with people with more than one seizure type. We have made a number of revisions to the scale. The objective of this study is to examine the psychometric properties of the revised seizure-severity scale. Further, to assess whether people with epilepsy could reliably differentiate between more than one seizure type and whether this would be reflected in subjects' scores.
MATERIALS AND METHODS
Modifications to the scale Four items were added to improve the content validity of the scale. Additions to the ictal/postictal scale were whether patients smacked their lips, fidgeted or behaved in an unusual way and whether they felt sleepy or not after a seizure. The percept scale additions were whether patients had seizures during the night or day and whether their seizures were clustered or not. The need to increase the responsiveness of the scale was addressed by adding a fifth response category to a four-items response choice for four of the items; the rationale for this was to make items more sensitive to the potential differences between simple and complex partial seizures and thus make the scale more responsive to potential treatment effects (e.g. the item about losing consciousness was revised to include a fifth response category: 'No I have not blanked out or lost consciousness').
A fifth response category was also added to items 4, 10, 12 and 19 (see Table 1 ).
Anecdotally a significant proportion of our patients were clearly able to describe the existence of two or even three types of seizures and they could differentiate them on the grounds of whether they were 'major' or 'minor' seizures. Therefore, it was decided that, as part of the further development of the scale, we would ask respondents who could identify both major and minor seizures to complete the scale: once about their minor seizures and one about their major seizures. We suggested that where patients could differentiate between two types of seizures that the most severe be referred to as the major seizure (being judged by whether or not they lost consciousness, duration of loss of consciousness, injury, time to recovery, and incontinence). The minor seizure, therefore, is that seizure which is the least severe. It is important to note that major and minor seizures do not refer to the Internation League Against Epilepsy (ILAE) classification.
Subjects
Ninety-seven patients with a clinical diagnosis of epilepsy uncomplicated by pseudoseizures and currently taking antiepileptic medication were recruited consecutively from a specialist epilepsy clinic in the U.K. Patients were asked to complete the scale based on seizures they had experienced in the last 4 weeks. The possible scoring ranges are between 7 and 32 for the percept scale and between 10 and 48 for the ictal/postictal scale. The higher the score the more severe the seizures. In addition to completing the seizure-severity scale for either one seizure type or both major and minor seizures, information was collected about their clinical and demographic details.
Statistical methods
The reliability of the scale was assessed in two ways: by examining the test-retest correlations and the internal consistency alpha13. We hypothesized that patients would be able to differentiate between their major and minor seizures and this would be reflected in their scores on the seizure-severity scale. Further evidence of the validity of the scale was sought by ' examining the correlation between scores on the scale relating to both the major and minor seizures.
RESULTS
There were 97 patients (48 males and 49 females) who completed the scale. The mean age of the sample was 32 years (range 15-70 years). Based on the ILEA classification of seizures 20% of respondents had simple partial seizures only, 60% complex partial seizures with or without secondary generalized seizures and 20% with primary generalized seizures only.
Of the 97 respondents 32 of them reported that they had experienced more than one seizure type and were able to differently classify their seizures as either 'major' or 'minor'. All 32 respondents completed their seizure-severity scale separately for both major and minor seizures.
Reliability of the seizure-severity scale for major and minor seizures Assessment of the internal consistency of the scale was conducted on scales completed by all 97 respondents. Thirty of those 32 subjects with multipleseizure types returned to the clinic to complete the seizure-severity scale a second time as part of the assessment of the test-retest reliability of the scale. The mean interval for the test-re-test was 14 days. None of the patients reassessed reported any significant change in their seizure severity or frequency and none had had a change in medication during the intervening period.
The internal consistency of the scale was 0.68 for the percept subscale and 0.86 for the ictal subscale when applied to major seizures, and 0.72 for the percept.and 0.78 for the ictal subscale when applied to minor seizures. Cronbach suggests that a score of 0.7 and above is acceptable for both clinical and research purposes .
I3 The test-retest scores (correlation coefficients) for the scale for both major and minor seizures are as follows: major percept subscale p = 0.96, major ictal subscale p = 0.93, minor percept subscale p = 0.72, minor ictal subscale p = 0.78. Table 2 presents the reliability scores for the original and revized seizure-severity scale.
Criterion validity of the seizure-severity scale for major and minor seizures Respondents who completed the scale for both seizure types (n = 32) were able to differentiate between major and minor seizures on the revized seizureseverity scale for both the ictal/postictal scale and the percept scale. There was significant difference for the mean scores of the ictal/postictal subscale (t = 6.13, df = 35, p c 0.01) and the percept scales (t = 2.51, df = 35, p = 0.02) (see Table 3 ).
DISCUSSION
While a reduction in the frequency of seizures is an important outcome in the treatment of epilepsy, other measures, including assessing the severity of seizures, also deserves consideration and have been the focus of recent research5*6.'0.". Current dissatisfaction with counting seizures alone has been discussed previously6 as have the merits of measuring patients' perception of seizure severity9.
We originally designed a 16-item, patient-based, seizure-severity scale that had good evidence of reliability and validity6 and sensitivity to change for the ictal/postictal scale 12, the latter being of crucial importance when such measures are used in clinical trials. Subsequent experience with the scale suggested that further development was necessary if the scale was to be accepted as a standard measure of efficacy for use in clinical trials. Consequently, four additional items were incorporated into the scale to improve its content validity. A fifth response category scoring zero has been added to three of the items to widen the gap between scores obtained for simple and complex partial seizures. These changes have the potential to improve detection of change attributable to drug treatment. The importance of catering for respondents with more than one seizure type was recognized. A simple method of asking respondents to differentiate between major and minor seizures now allows for them to complete the scale separately for each seizure type and monitor changes in their seizures where they have more than one seizure type. This approach, however, is only suitable for clinical trials where the different seizure types, as perceived by the patient, can be clarified with a trained investigator and could not be reliably used in postal questionnaires.
The revised seizure-severity scale is both reliable and valid and maybe more sensitive to the effects of novel antiepileptic drug treatment. The percept is less likely to be amenable to change and therefore is not recommended for use in clinical drug trials.
In conclusion, a valid measure of seizure severity is important if we are to fully understand the impact of novel AEDs in clinical trials. We have made a number of improvements to the Liverpool Seizure Severity Scale in order to enhance its reliability, validity and responsiveness. Further evidence of the validity and responsiveness of the scale is necessary if it is to be acceptable as a standardized measure of seizure severity in clinical trials. The utility of the revised seizure-severity scale is being evaluated in add-on trials of remacemide, tiagabine, lamotrigine and topirimate. The seizure-severity scale has been translated into several different languages using forward and backward translation technique. A child's version of the scale has also been developed14. Finally, the seizure-severity scale forms an integral part of a health-related quality of life measure", within which the aim is not to provide an alternative measure to seizure frequency but a complimentary one which will enhance our understanding of the impact of epilepsy and its treatment.
